

# Driving the Future of Intervention™



# Safe Harbor Statement



This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, Inc. and its subsidiaries. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: market conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system; uncertainty in the results of regulatory pathways and regulatory approvals and the development of future versions or applications for the system; uncertainty resulting from political, social and geopolitical conditions; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; maintenance of intellectual property rights; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

# Pivotal Company Development

September 2025

## BREAKING NEWS



The FDA has granted 510(k) clearance for the LIBERTY® Endovascular Robotic System



November 2025



### **Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.**

*Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership*

*Interest and Overwhelmingly Positive Feedback from Physicians and Hospital Administrators at Recent Meetings Validates Limited Market Release of LIBERTY®*

**HINGHAM, Mass., November 5, 2025** – Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that its LIBERTY® System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures, is now commercially available in the U.S. The Limited Market Release (LMR) will introduce LIBERTY® to selected high procedure volume regions where the Company already experienced preliminary demand for LIBERTY®. The LMR will focus on collecting real-world insights from potential high-volume users to guide responsible growth and ensure consistent quality and performance, leading to the expected Full Market Release (FMR) during the Society of Interventional Radiology (SIR), the largest U.S. medical conference for Interventional Radiology, in April 2026.

"We are excited to enter the commercialization phase of LIBERTY®. We are building a new robotic category with the introduction of LIBERTY®, the world's first single-use robotic

# Pivotal Company Development



## **Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System**

Microbot Medical Inc.  
November 26, 2025 • 4 min read



## **Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System**


Microbot Medical Inc.  
Tue, February 24, 2026 at 8:30 AM EST • 5 min read



# The Market

# Robotic Assisted Surgery Market is Big and Growing...

**Robotic Assisted Surgery Market Size, Global**  
2019-2030



# ...So No Wonder Everyone Wants to Play in it...

### RAS Companies, excluding China (n=131)

A collection of 131 logos for Robotic Assisted Surgery (RAS) companies from various countries, including the USA, Europe, and Asia. The logos are arranged in a grid-like fashion. Some logos are enclosed in dashed blue boxes, while others are not. The companies include:

- Artec, Artedrone, AKTORmed, Amplitude, AiM, AIRS, Aesculap, ASCAR, basecamp, BRAINLAB, biobot, ACCURAY, ACUSURGICAL, ASENSUS, ACOUSTIC MEDSYSTEMS, ANDROMEDA, BRAIN NAVI, b, denob, CAPSTAN, COLLIN, CASCINATION, CYBER SURGERY, CARANX MEDICAL, Catheter Precision, CVR, CONVERGENCE, caira, CORIN, CLEARPOINT, Dex Surgical, Distalmotion, ENDOROBOTICS, ELMED, ENDOQUEST, FMED, GANYMED, EndoMaster, ecential, edap, EndoWays, Flex Perc Medical, FORSIGHT, free hand, FLUX, GLOBUS, GALEN, HUMAN, XTENSIONS, iotamotion, insight, INSIGHT-TEC, INTUITIVE, Johnson & Johnson, Leica, LN, Levita, LAZA, LEM, LEM surgical, MONTERRIS, microsure, MENAERA, MMI, MORAY, MOMENTIS, MOON, medipixel, monogram, Medtronic, Mediaroid, MASMEC, meerecompany, neuro42, Noah Medical, NITINOTES, NIMBLE, NDR, neocis, OLYMPUS, Perceptive, PROCEPT, panda, Perfint, Proprio, ROBOSSIS, ROEN, Robocath, RIVERFIELD, rob surgical, RENISHAW, stryker, SIEMENS Healthineers, sentante, QUANTUM, SSii, THERACLION, TAUREAN, TAMAR, USMI, TRITON, Neptune, smith&nephew, STEREO, Endoluminal, SIVA, Soteria, ZEISS, THINK, synaptive, telos, VIRTUAL, VICARIOUS, VIRTUOSO, VENUS, X surgical, ZAP, ZIMMER BIOMET, ZETA SURGICAL, Xcath.

### Chinese RAS Companies (n=57)

A collection of 57 logos for Chinese Robotic Assisted Surgery (RAS) companies. The logos are arranged in a grid-like fashion. Some logos are enclosed in dashed blue boxes, while others are not. The companies include:

- abrobo, Angio8, AGILIS, 奥朋医疗, BORN, Cornerstone, 核动医疗, 长木谷, 迪视医疗, EDGE, EASYAPLOON, FUJIFILM, 伏羲九针, GREAT, DCARER, HURWA, FU, LANGK, LANGK INTERVENTION, LANGK, HAMESH, 华志医疗, 哈尔滨德善智能医疗设备股份有限公司, KPS, 科鹏外科, KMOY, KEYIN, KowTech, LONGWELL, MicroPort, NI, NAVI SEED, 纳策, 梅奥心磁, MEIO MEDICAL, Panther, 源尔特医疗, 键嘉, 盘古机器人, Rain Med, ROSSUM, RobPath, LANCET, B, IT, RONOVO, ROBO, 水锐, SHURUI, Sinovation, 华科精准 | 华科恒生, 圣安本医疗, TINAVI, 天智航, TUDAO, ULTRAST, VAS, Wire Science, WeMed, WEGO, ORTHO, 铸正, ZOEZEN.



# Endovascular Is a Clear Blue Ocean




## Laproscopy

## Endoluminal

## Microsurgery

FDA  
Clearance/  
Approval



## Hard Tissue



## Soft Tissue

## Vascular Navigation

FDA  
Clearance/  
Approval




# USA Endovascular Market



# Large and Emergent Market

- **>6 million annual endovascular procedures performed in the US (15 million worldwide)**
- **>\$40B spent annually** in the US
- Performed by **15,000 physicians**
  - 9,000 interventional cardiologists
  - 3,000 interventional radiologists<sup>1</sup>
  - 3,000 vascular surgeons
- Performed at **8,000 facilities**
  - 3,500 hospitals
  - 4,500 ambulatory centers (ASCs/OBLs)
- Many **endovascular procedures are emergent**, life and limb saving interventions


## US Market Endovascular Procedures Performed Annually



**>6M Procedures Performed Annually in the US (15M Worldwide)**

# Supported by Interventionalists

**Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future?**





# Growing Unmet Needs

AMA's 2026 public health initiative calls for expanded **radiation safety protections** and **ergonomic workplace design** to reduce clinician injury and improve long-term workforce health.<sup>1</sup>



## Radiation & Ergonomic Risks<sup>2</sup>

### Interventionalists have:

- 6× higher risk of cataracts
- 3× higher risk of malignancy

### Ergonomic / Musculoskeletal Risks:

- 66% reported musculoskeletal pain related to wearing lead protective equipment
- 60% reported at least one orthopedic injury



## Staff Shortage

- IR is ranked 2nd in specialties facing the greatest physician shortages<sup>3</sup>
- Healthcare faces staff shortages of 85K+ by 2036<sup>4</sup>
- Nearly 50% of physicians report burnout<sup>4</sup>
- 1 in 5 physicians report experiencing depression, exacerbating workforce gaps<sup>4</sup>



## Access to Quality Care<sup>5</sup>

- 20% of Americans live in rural areas where only 10% of doctors practice
- 80% of rural Americans are medically underserved
- ~200 rural hospitals have closed since 2005

# Endovascular Robotics: Limited Adoption

**CURRENT  
PENETRATION:  
LESS THAN  
1%  
OF PROCEDURES  
DONE ROBOTICALLY<sup>1</sup>**

# The Barriers

# Multiple Barriers Leading to Low Penetration



Extended  
set-up time



Special training,  
Long learning curve




Large  
footprint



Capital  
expense



Cumbersome  
and expensive  
disposables



Dedicated  
infrastructure

# Change the Conversation

# The Solution

# A New Robotics Category

Fully Disposable & Single-use Robotic System is Designed for Access and Adoption

## External Benefits

- Single-use, disposable system eliminates capital and infrastructure costs
- Sterile, ready-to-use design enables rapid setup
- No capital investment removes upfront costs and long-term risks
- No service contracts or annual service agreements required

## Internal Benefits

- First mover advantage
- Predictable recurring revenue from hospital utilization
- Faster sales cycle for quicker acquisition
- Disposable components only reduce operational expenses
- No field service needed, further reducing operational expenses


# Differentiated Robotic Solution

The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures

- Single-use, fully-disposable without need for capital investment
- Empowers physicians to precisely steer guidewires and catheters using a handheld remote control away from the radiation source
- Small footprint that integrates into current procedure workflow
- No additional infrastructure required by the user
- Simple and intuitive set-up in under 5 minutes
- Short-learning curve to proficiency
- Compatible with off the shelf guidewires and catheters



# Initial Target Market: Peripheral Vascular



INITIAL TARGET  
PROCEDURES (USA):

**2.3M**

ANNUAL  
SPENDING (USA):

**\$15B**

TARGET  
PHYSICIANS (USA):

**6,000**

AVG. ANNUAL # OF  
PROCEDURES PER  
PHYSICIAN (USA):

**~400**

FACILITIES PERFORMING  
PROCEDURES (USA):

**2,200 Hospitals**  
**1,000 Ambulatory  
Centers**

# Clinical Outcomes from ACCESS-PVI

Robotic manipulation of guidewires and catheters with LIBERTY<sup>®</sup> was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile<sup>1</sup>

Achieved  
**100%**  
Robotic Navigation  
Success  
in Every Case  
(N = 20)

**92%**  
Relative  
Reduction  
in  
Radiation  
Exposure

**NO**  
Adverse  
Device Events  
Reported  
(ADE = 0%)

Participating  
Physicians Reported  
LIBERTY Performed  
as Planned with  
**100%**  
Satisfaction

# First Mover Advantage

LIBERTY<sup>®</sup> was designed to eliminate barriers and enable adoption of robotics in endovascular procedures

Barriers to Adoption	Other Robotic Systems	LIBERTY <sup>®</sup> Endovascular Robotic System
Cost of acquisition	<ul style="list-style-type: none"> <li>✓ Large capital investment</li> <li>✓ Disposable procedure kit</li> <li>✓ Annual service agreement</li> </ul>	<ul style="list-style-type: none"> <li>✓ Single-use (disposable) device with no initial acquisition cost</li> </ul>
Procedure set-up time	<ul style="list-style-type: none"> <li>✓ 20 minutes extra compared to conventional surgery<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>✓ 5 minutes to set-up the robot<sup>3</sup></li> </ul>
Learning curve	<ul style="list-style-type: none"> <li>✓ Average 40-100 cases depending on the procedure<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>✓ Less than 5 cases<sup>3</sup></li> </ul>
Device compatibility	<ul style="list-style-type: none"> <li>✓ Some require use of proprietary instruments and devices</li> </ul>	<ul style="list-style-type: none"> <li>✓ Compatible with off-the-shelf instruments and devices</li> </ul>
Complex integration	<ul style="list-style-type: none"> <li>✓ Requires a dedicated room and integration with hospital IT systems</li> </ul>	<ul style="list-style-type: none"> <li>✓ Can be used in any angio-suite and does not need to connect with hospital IT</li> </ul>

1. Analysis of Procedure Time in Robot-Assisted Surgery: Comparative Study in Laparoscopic Cholecystectomy, Computer Aided Surgery, 8:1, 24-29, DOI: 10.3109/10929080309146099.

2. Systematic review of learning curves in robot-assisted surgery; BJS Open 2020; 4: 27-44.

3. Research report from wet-lab with nine experienced interventional radiologists. Set-up times and learning curve will vary with user.

# First Mover Advantage



LIBERTY<sup>®</sup> is the only commercially robotic system available in the US for peripheral endovascular procedures

Several companies are developing robotic solutions due to the attractive market and untapped potential  
Microbot is uniquely positioned for success with our unique design and first mover advantage in the US market

Company	Status	Target Procedures	USA Commercial Availability	No Capital Equipment	No Maintenance Required	No Infrastructure Required	Competitive Outlook
	On the Market (U.S.)	Peripheral Vascular	✓	✓	✓	✓	CE Mark expected in late in 2026; will explore additional markets that leverage FDA clearance.
	On the market (Europe, China)	Cardiology	✗	✗	✗	✗	Focused on Europe & China. Large capital system with high cost and complex integration.
LN ROBOTICS	On the market (Korea only)	Cardiology	✗	✗	✗	✗	Focused on Korea. Large capital system with high cost and complex integration.
	Development stage	Neurovascular	✗	✗	✗	✗	Exited US cardiology market. Changed strategy from PCI to focus on Neurovascular.
(Latvia)	Development stage	Peripheral Vascular	✗	✗	✗	✗	Completed one case in humans. Clinical, regulatory and operational complexity are unknown.
	Development stage	Neuro Vascular	✗	✗	✗	✗	Pre-clinical. Focused on telerobotics with magnetic steering. Cost and operational complexity are unknown.

# Attractive Reimbursement



Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY®

Procedure	Description	CPT Code(s)	Avg. Reimbursement
<b>Y90 for Liver Cancer</b>	Part 1 – Mapping procedure Part 2 – Embolization procedure	Dx Angiogram (75726) Coil placement (37242) Embolization (37243) Y90 particles (C2616)	<b>\$43,990.21</b>
<b>Peripheral Embolization</b>	For BPH, Uterine Fibroids, Hemorrhoids, Knee Osteoarthritis	Dx Angiogram (75726) Bland particle embolization (37242)	<b>\$15,734.00</b>
<b>Lower Limb Revascularization</b>	Below the knee Chronic total occlusions	Dx Angiogram (75726) Angioplasty (37242)	<b>\$15,856.00</b>
<b>Vascular Hemorrhage</b>	Place intravascular coils or glue to stop bleeding	Dx Angiogram (75726) Coil placement (37244)	<b>\$15,734.00</b>

2024 Medicare/Medicaid average reimbursement  
Actual reimbursement will vary and may be adjusted for cost of living  
Private insurance typically billed at a higher rate

# Unique Business Model

The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders

## No Capital Investment

- No special Capital Expense (CAPEX) approval required by the customer. LIBERTY® can be purchased from the Operational Expense (OPEX) budget which will expedite the purchasing process.
- Cost effective evaluation process for customers at their facility can expedite purchasing decision.
- Eliminates the Company's investment in an expensive upfront and ongoing capital equipment inventory build-up, shipping, storage and management.

## No Maintenance Expense

- Eliminates the cost for Microbot to hire, train, and manage a dedicated field service department.
- Eliminates the cost for Microbot to build dedicated warehouses and maintain inventory of replacement parts.
- Eliminates the cost for customers to pay for service and maintenance expenses.
- Eliminates risk of equipment down time.

## No Custom Infrastructure

- Eliminates the process of fitting the technology to each specific customer (and sometime within a health system), to reduce expenses and expedite purchasing decision.
- Eliminates the investment in establishing, training, supporting and supplying technical team to support installations.
- LIBERTY® does not require investment in dedicated customer staff to provide on-going robotic program support.

## Continuous Consumable Revenue

- Recurring revenue stream based on per device usage (or more) for a single procedure.
- LIBERTY® is a single SKU (Stock Keeping Unit) that can be utilized across many procedures, physicians and departments.

# Commercialization Timeline

Successful execution of regulatory, commercial and launch readiness strategies



Commercial Leadership team

Q2  
2025



Manufacturing & Inventory Build

Q2  
2025



FDA Marketing Authorization

Q3  
2025



Sales Team Recruitment & Training

Q3  
2025



Commence Marketing & Sales Initiatives

Q3  
2025



LIBERTY® Limited market Release

Q4  
2025



Full LIBERTY® Launch

Q2  
2026

# Go-to-Market Strategy



Company positioned to accelerate market adoption of the LIBERTY® system

- Dedicated direct sales team in the U.S., supplement with distribution channels as needed
- Increase manufacturing and build inventory levels to meet anticipated demand
- Limited Market Release (LMR) in Q4 2025 followed by a Full Market Release (FMR) expected in early 2026

# Building for Comprehensive Growth

Future growth will come from access to new markets (EMEA, Canada, etc.), spaces (cardiology, neurovascular) and usability (tele-intervention)

**Active R&D Pipeline:** Focused on next-generation robotic system that allows for increased usability in existing space (deep) and entering new spaces (wide).

**Ongoing Development:** Tele-intervention and autonomous robotics programs in progress.

**Build a direct sales team in the U.S.** from 4 to 12 territories by end of the year.

**Expand to new markets:** Establish commercial and operational infrastructure to support expansion into EMEA (Europe, Middle East, Asia).

**Pursue CE Mark:** Supplement FDA clearance to enter markets based on respective regulatory requirements.



# Financial Strength

**Capital-efficient operating model** by eliminating upfront and ongoing expensive equipment inventory, logistics, and field service.

**Frees capital to invest** in high-return growth drivers, including Sales, Marketing, and Pipeline Development, enhancing shareholder value.

**Strong balance sheet** with ~\$80M in cash by YE 2025 and a ~\$2.5M/month burn rate in 2026, providing a favorable cash runway.



# Global Intellectual Property Portfolio

LIBERTY<sup>®</sup> is protected by a strong and growing intellectual property portfolio.



**20**  
patents  
issued  
worldwide

**52**  
patents  
pending

# Experienced Management Team



**Harel Gadot**  
CEO, President & Chairman  
[LinkedIn](#)



**Simon Sharon**  
Chief Technology Officer  
[LinkedIn](#)



**Juan Diaz-Cartelle, MD**  
Chief Medical Officer  
[LinkedIn](#)



**Rachel Vaknin**  
Chief Financial Officer  
[LinkedIn](#)



**Earl Adamy**  
Vice President of Strategic  
Marketing & Business Dev  
[LinkedIn](#)



**Eran Cohen**  
Vice President  
of Global Integration  
[LinkedIn](#)



**Naama Moav**  
Vice President of HR  
[LinkedIn](#)



**Noa Ofer**  
Vice President of QA & RA  
[LinkedIn](#)

# Proven Commercial Leadership Team



**Christina Bailey**  
Vice President of Sales USA  
[LinkedIn](#)



**Alon Tamir**  
Vice President of EMEA  
[LinkedIn](#)



**Allison Rosefort**  
Vice President of Marketing  
[LinkedIn](#)



**Justin Bourne**  
Director of Sales  
[LinkedIn](#)



**Elaina Romano**  
Sr. Director Internal Operations  
[LinkedIn](#)



**Dani Kulp**  
Director, Sales Training  
[LinkedIn](#)



**Michael Lytle**  
Manager, Sales Operations  
& Analytics  
[LinkedIn](#)



**Lisa Dobbins**  
Sr. Director, Human Resources  
[LinkedIn](#)



# The Reason to Believe

Being the first and only robotic system for PI in the USA, and meeting its planned milestones in 2025, Microbot Medical is poised to build on this momentum in 2026.



**FDA Clearance** obtained



**Secured U.S. Based Logistics Partner** to Support Commercialization



**Completed the Recruitment and onboarding** of the Commercial Leadership Team



**Limited Market Release (LMR)** Commenced as plan



**Initial Customers** Emory University Hospital, Tampa General Hospital, and other accounts



**Strengthened Balance Sheet** ~80M available to Drive Commercialization Activities



**Full Market Release** ~On Target for FMR



Contact Investor Relations

[ir@microbotmedical.com](mailto:ir@microbotmedical.com)

NASDAQ CM: MBOT

